Brief: Ribomic Completes IND Submission For Observational Study For Continuous Phase 2 Trial Of RBM-007
19/04/2022 14:20
April 19 (Reuters) - Ribomic Inc 4591.T :
* RIBOMIC ANNOUNCES COMPLETION OF IND SUBMISSION FOR AN
OBSERVATIONAL STUDY FOR CONTINUOUS PHASE 2 TRIAL OF RBM-007 FOR
TREATMENT OF ACHONDROPLASIA
Source text for Eikon: ID:nBw7n1JDYa
Further company coverage: 4591.T
((Reuters.Briefs@thomsonreuters.com;))